Algazy, Kenneth External Author

Publications

Sort by

Selected publications

  • A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancerJNCCN Journal of the National Comprehensive Cancer Network2012 Academic Article GET IT
    Times cited: 8